320 related articles for article (PubMed ID: 15100729)
1. [The clinic significance of urinary podocytes in patients with focal segmental glomerulosclerosis].
Li YH; Huang HC; Liu G; Zhang YK
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):135-8. PubMed ID: 15100729
[TBL] [Abstract][Full Text] [Related]
2. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
Eriguchi M; Yotsueda R; Torisu K; Kawai Y; Hasegawa S; Tanaka S; Noguchi H; Masutani K; Kitazono T; Tsuruya K
Am J Physiol Renal Physiol; 2016 Feb; 310(4):F322-33. PubMed ID: 26632605
[TBL] [Abstract][Full Text] [Related]
3. Urinary podocytes in primary focal segmental glomerulosclerosis.
Hara M; Yanagihara T; Kihara I
Nephron; 2001 Nov; 89(3):342-7. PubMed ID: 11598401
[TBL] [Abstract][Full Text] [Related]
4. Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.
Pérez V; López D; Boixadera E; Ibernón M; Espinal A; Bonet J; Romero R
BMC Nephrol; 2017 Feb; 18(1):49. PubMed ID: 28158993
[TBL] [Abstract][Full Text] [Related]
5. Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients.
Navarro-Muñoz M; Ibernon M; Pérez V; Ara J; Espinal A; López D; Bonet J; Romero R
Nephrol Dial Transplant; 2011 Dec; 26(12):3914-23. PubMed ID: 21414970
[TBL] [Abstract][Full Text] [Related]
6. Urinary fibrinogen and renal tubulointerstitial fibrinogen deposition: Discriminating between primary FSGS and minimal change disease.
Wang Y; Zheng C; Xu F; Liu Z
Biochem Biophys Res Commun; 2016 Sep; 478(3):1147-52. PubMed ID: 27539323
[TBL] [Abstract][Full Text] [Related]
7. Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome.
Wagrowska-Danilewicz M; Stasikowska O; Danilewicz M
Pol J Pathol; 2006; 57(1):17-21. PubMed ID: 16739878
[TBL] [Abstract][Full Text] [Related]
8. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
[TBL] [Abstract][Full Text] [Related]
9. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Ebihara I; Koide H
Am J Nephrol; 2000; 20(3):175-9. PubMed ID: 10878397
[TBL] [Abstract][Full Text] [Related]
10. Podocyte mRNA in the urinary sediment of minimal change nephropathy and focal segmental glomerulosclerosis.
Szeto CC; Wang G; Chow KM; Lai FM; Ma TK; Kwan BC; Luk CC; Li PK
Clin Nephrol; 2015 Oct; 84(4):198-205. PubMed ID: 26308082
[TBL] [Abstract][Full Text] [Related]
11. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R; Gagliardini E; Ruggiero B; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F335-41. PubMed ID: 26697986
[TBL] [Abstract][Full Text] [Related]
12. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.
Garin EH; Mu W; Arthur JM; Rivard CJ; Araya CE; Shimada M; Johnson RJ
Kidney Int; 2010 Aug; 78(3):296-302. PubMed ID: 20485332
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Glomerular Transcriptome Profiles of Adult-Onset Steroid Sensitive Focal Segmental Glomerulosclerosis and Minimal Change Disease.
Tong J; Xie J; Ren H; Liu J; Zhang W; Wei C; Xu J; Zhang W; Li X; Wang W; Lv D; He JC; Chen N
PLoS One; 2015; 10(11):e0140453. PubMed ID: 26536600
[TBL] [Abstract][Full Text] [Related]
14. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
Cara-Fuentes G; Venkatareddy M; Verma R; Segarra A; Cleuren AC; Martínez-Ramos A; Johnson RJ; Garg P
Pediatr Nephrol; 2020 Oct; 35(10):1887-1896. PubMed ID: 32399663
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin G/albumin staining in tubular protein reabsorption droplets in minimal change disease and focal segmental glomerulosclerosis.
Bu L; Mirocha J; Haas M
Nephrol Dial Transplant; 2021 May; 36(6):1016-1022. PubMed ID: 32191308
[TBL] [Abstract][Full Text] [Related]
16. Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis.
An JN; Hyeon JS; Jung Y; Choi YW; Kim JH; Yang SH; Oh S; Kwon S; Lee SH; Cho JH; Park SH; Ha H; Kim DK; Lee JP; Hwang GS
Sci Rep; 2019 Oct; 9(1):14707. PubMed ID: 31605028
[TBL] [Abstract][Full Text] [Related]
17. Reduced INF2 expression in nephrotic syndrome is possibly related to clinical severity of steroid resistance in children.
Tamura H; Nakazato H; Kuraoka S; Yoneda K; Takahashi W; Endo F
Nephrology (Carlton); 2016 Jun; 21(6):467-75. PubMed ID: 26383224
[TBL] [Abstract][Full Text] [Related]
18. Urinary soluble HLA class I antigen in patients with minimal change disease: a predictor of steroid response.
Park CW; Song HC; Shin YS; Ahn SJ; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
Nephron; 1998; 79(1):44-9. PubMed ID: 9609461
[TBL] [Abstract][Full Text] [Related]
19. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.
Ramezani A; Devaney JM; Cohen S; Wing MR; Scott R; Knoblach S; Singhal R; Howard L; Kopp JB; Raj DS
Eur J Clin Invest; 2015 Apr; 45(4):394-404. PubMed ID: 25682967
[TBL] [Abstract][Full Text] [Related]
20. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis.
Deegens JK; Dijkman HB; Borm GF; Steenbergen EJ; van den Berg JG; Weening JJ; Wetzels JF
Kidney Int; 2008 Dec; 74(12):1568-76. PubMed ID: 18813290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
